Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Saredutant · 13 trials · 5 indications
| Arm | Type | Description |
|---|---|---|
| Saredutant 100mg and Paroxetine 20 mg | EXPERIMENTAL | combined saredutant 100mg and paroxetine 20mg once daily for a maximum of 8 weeks |
| Saredutant 30mg and Paroxetine 20mg | EXPERIMENTAL | combined saredutant 30mg and paroxetine 20mg once daily for a maximum of 8 weeks |
| Paroxetine 20 mg and saredutant placebo | ACTIVE_COMPARATOR | paroxetine 20mg and saredutant placebo once daily for a maximum of 8 weeks |
| Placebo | PLACEBO_COMPARATOR | Saredutant placebo and paroxetine placebo once daily for one week during screening period and maximum of 8 weeks for the active phase |
| Saredudant/Escitalopram | EXPERIMENTAL | Saredutant 100 mg and Escitalopram 10 mg once daily for a maximum of 8 weeks |
| Placebo and Escitalopram | ACTIVE_COMPARATOR | Placebo for saredutant and Escitalopram 10 mg once daily for a maximum of 8 weeks |
| Saredutant 100 mg | EXPERIMENTAL | Saredudant100 mg once daily for a maximum of 32 weeks |
| Escitalopram 10 mg | ACTIVE_COMPARATOR | Escitalopram 10 mg once daily for a maximum of 32 weeks |
| Saredutant 30 mg | EXPERIMENTAL | Saredutant 30 mg once daily for a maximum of 8 weeks |
| Name | Type | Description |
|---|---|---|
| saredutant (SR48968) | DRUG | oral administration,capsules |
| paroxetine | DRUG | oral administration, capsules |
| placebo | DRUG | oral administration, capsules |
| escitalopram | DRUG | oral administration, capsules |
| Saredutant | DRUG | - |
| Saredutant (SR48968C) | DRUG | oral administration (capsules) |
| Saredutant succinate (SR48968C) | DRUG | - |
Inclusion Criteria: * Outpatients with recurrent Major Depressive Disorder Exclusion Criteria: * Symptoms of current depressive episode for less than 30 days or more than 2 years * Mild depression, as measured by standard clinical research scales * Significant suicide risk * Lack of sexual activi...
Saredutant is an investigational small molecule being studied for the treatment of psychiatric conditions, including major depressive disorder and generalized anxiety disorder. It has been evaluated in Phase 3 clinical trials for these indications. As of the available data, Saredutant remains investigational and has not been approved by regulatory authorities.
Saredutant is being developed by Sanofi, a multinational pharmaceutical company listed on the stock exchange under the ticker symbol SNY. Sanofi has sponsored multiple clinical trials to evaluate the efficacy and safety of Saredutant in patients with depression and generalized anxiety disorder.
Saredutant has reached Phase 3 clinical development, the final stage of testing before potential regulatory submission. All eight recorded trials for Saredutant have been completed, with no active trials currently ongoing. The drug remains investigational, meaning it has not yet received approval from regulatory agencies.
Saredutant has been studied in several Phase 3 trials, including NCT00336713, a long-term study in patients with depression; NCT00390533 and NCT00417118, eight-week studies in generalized anxiety disorder; and NCT00429260, a study on abrupt discontinuation in depression. These trials collectively enrolled over 1,300 participants across multiple countries.
Saredutant is a distinct investigational compound developed by Sanofi. No alternative names or brand names have been associated with Saredutant in the clinical trial data. It is identified solely by its generic name in all registered studies.
Saredutant is a small molecule developed for psychiatric indications. Its specific molecular target has not been disclosed in the available clinical trial information. The drug has been evaluated for its effects on symptoms of depression and anxiety in controlled clinical studies.